First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2726-2734

  Painter, Wendy ^a   Robertson, Alice ^a   Trost, Lawrence C ^a   Godkin, Susan ^a   Lampert, Bernhard ^a   Painter, George ^a  

^a Chimerix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CREATINE KINASE; CREATININE; ELECTROLYTE; PLACEBO;

ABDOMINAL PAIN; ADULT; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DNA VIRUS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NEUTROPHIL COUNT; NORMAL HUMAN; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UREA NITROGEN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULE ENDOSCOPY; CYTOSINE; DNA VIRUSES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; HUMANS; INTRAOCULAR PRESSURE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PLACEBOS; UNITED STATES;

EID: 84860188140     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05983-11     Document Type: Article

References (20)

1. 14C] cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 63:678-681.
2. Bruno B, et al. 2003. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol. Blood Marrow Transplant. 9:341-352. (Pubitemid 38351819)
3. Cihlar T, et al. 1999. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol. 56:570 -580.
4. Cihlar T, Ho ES, Lin DC, Mulato AS. 2001. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20:641-648. (Pubitemid 32821831)
5. Cundy KC, et al. 1995. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39:1247-1252.
6. De Clercq E. 2003. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16:569-596. (Pubitemid 37296550)
7. Emery VC. 2001. Progress in understanding cytomegalovirus drug resistance. J. Clin. Virol. 21:223-228. (Pubitemid 32496541)
8. Hostetler KY. 2009. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res. 82:A84-A98.
9. Ison MG, Hayden FG. 2002. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr. Opin. Infect. Dis. 15:355-367. (Pubitemid 34816423)
10. Ison MG. 2005. Respiratory viral infections in transplant recipients. Curr. Opin. Organ Transplant. 10:312-319. (Pubitemid 41689775)
11. Ison MG. 2006. Adenovirus infections in transplant recipients. Clin. Infect. Dis. 43:331-339. (Pubitemid 44078906)
12. Jacobsen T, Sifontis N. 2010. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am. J. Health Syst. Pharm. 67:1417-1425.
13. Lalezari JP, et al. 1995. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl] cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171:788-796.
14. Lanier R, et al. 2010. Development of CMX001 for the treatment of poxvirus infections. Viruses 2:2740-2762.
15. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712.
16. Painter RG, et al. 2008. CMX001: anti-smallpox agent, anticytomegalovirus agent, viral polymerase inhibitor. Drugs Future 33:655.
17. Razonable RR, Emery VC. 2004. Management of CMV infection and disease in transplant patients. Herpes 11:77-86. (Pubitemid 40064892)
18. Tan CS, Koralnik IJ. 2010. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 9:425-437.
19. Tippin TK, Lampert BM, Painter GP, Lanier R. 2010. Lipid conjugates of cidofovir and tenofovir, CMX001 and CMX157, are not substrates of human organic anion transporters OAT1 and OAT3, poster T3396. Am. Assoc. Pharm. Sci. Annu. Meet., New Orleans, LA, 14 to 18 November 2010. American Association of Pharmaceutical Scientists, Arlington, VA.
20. Uwai Y, Ida H, Tsuji Y, Katsura T, Inui K-I. 2007. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res. 24:811-815. (Pubitemid 46411965)